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one of the most important recent advances in our under-
tanding of the basic mechanisms of genetic cardiac disease
as been the central role played by mutations in structural
roteins. Nearly 2 decades ago Geisterfer-Lowrance et al.
1) published the first linkage of a mutation in the beta-
yHC gene to hypertrophic cardiomyopathy (HCM). Since
hat seminal finding, mutations in a broad array of proteins
hat contribute to the structural and functional integrity of
omponents of the cardiac sarcomere, myocellular cytoskel-
ton, and the sarcolemma have been definitively linked to a
ast range of clinical cardiomyopathies (2). Sarcomeric
rotein mutations represent a particularly intriguing subset
f the genetic cardiomyopathies in that independent muta-
ions within the same gene and often within the same
unctional domain can cause widely divergent, clinically
elevant patterns of pathogenic ventricular remodeling.
See page 320
To date, mutations in virtually all of the known sarco-
eric proteins have been associated with dilated cardiomy-
pathy (DCM) (3). Although the phenotypic variability
hat is characteristic of the HCM-linked sarcomeric gene
utations is also present in the DCM subgroup, important
linical similarities have been identified. In 2001 an exten-
ive multi-kindred study first linked mutations in MHY7
nd TNNT2 to DCM. Of note, a high frequency of
arly-onset ventricular dilation and congestive heart failure
n children and young adults, extensive early sudden cardiac
eath, and no evidence of the signature histopathological
ndings of HCM were observed, supporting the hypothesis
hat the observed dilation was a primary event, as opposed
o a secondary end point of hypertrophic heart disease (4). A
ubsequent report not only identified novel DCM-
ausing mutations in genes encoding the thin filament
roteins cTnC and cTnT, it further confirmed the
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arcomeric protein mutations (5).
In this issue of the Journal, Lakdawala et al. (6) present
he first extensive linkage study to establish the pathogenic-
ty of alpha-tropomyosin (TM) in DCM. The patient
ohort is particularly robust, encompassing 2 unrelated,
ultigenerational families that carry an aspartate-to-
sparagine substitution at residue 230 of TMP1 (D230N).
oth the large sizes of the affected families and the wealth
f available clinical information (including the childhood
resentation of disease for several adults) result in a partic-
larly informative match between genotype and phenotype.
Several aspects of the clinical expression in affected
ndividuals are notable. First, the initial presentation is
bimodal,” occurring either in early childhood (including a
triking number of infants with severe left ventricular
ystolic failure) or in middle age, where mild, largely
symptomatic left ventricular dilation is observed. Second,
he clinical response to supportive and standard medical
eart failure therapy was substantial because of a significant
nd sustained improvement in contractile function that was
bserved in 3 of 5 children presenting in infancy, an
nteresting finding in an autosomal-dominant disorder
aused by a structural mutation. Note that the improvement
as not universal; 2 individuals (one from each family)
iagnosed in childhood required cardiac transplantation in
arly adulthood and another died during the initial heart
ailure workup at age 13 years. Third, although most of the
ffected patients presenting in middle age are asymptomatic,
everal exhibit evidence of ongoing or triggered remodeling,
uggesting a subclinical decrease in baseline function that
ay represent a continuing susceptibility to cardiac stress
onferred by the presence of the D230N TMP1 substitu-
ion. Thus, the current study both confirms and signifi-
antly extends our understanding of the sarcomeric DCM
henotype.
The family studies are complemented and extended by a
eries of in-solution in vitro assays to evaluate the potential
ffect of the TMP1 D230N substitution on contractile
unction at the level of the cardiac sarcomere. Incorporation
f a human TM carrying the D230N mutation in the
ctin-TM–activated ATPase assay revealed a significant
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January 26, 2010:330–2 Tropomyosin and DCMecrease in both the Ca2 dependence of ATPase activity
nd the maximal ATPase activity as compared with both
ild-type and the previously described HCM-linked
175N mutation. In addition, a marked decrease in the
a2 affinity and cooperativity of Ca2 binding to cTnC
as observed in reconstituted thin filaments carrying the
MP1 D230N substitution. These findings are in full
greement with previous studies in which the investigators
sed DCM mutations linked to thin filament proteins and
upport the proposed hypothesis that DCM-linked sarco-
eric mutations decrease force generation and lead to a
rimary dilation of the left ventricle (7,8).
It has been suggested that sarcomeric cardiomyopathies
epresent the epitome of the interplay between structure and
unction. It is illustrative to note that mutations in TMP1
hat cause cardiomyopathies are relatively rare and are
lustered in discrete regions of the protein. The link
etween structure and function in TM is precise. Alpha-
ropomyosin can reside in 1 of 3 positions or “states” along
he actin filament that are determined by the Ca2 binding
tate of cTnC. At low Ca2, TM is localized to the outer
omain of actin and participates in an effective block of the
yosin binding site on actin, thus preventing the formation
f the work-performing cross bridges that drive contraction.
t high Ca2, a complex set of allosteric changes in the
rotein-protein interactions that govern the dynamic posi-
ion of TM are activated with a resultant shift of the
olecule to the inner actin domain, allowing for full myosin
ead access and strong cross-bridge formation.
It is important to note that these movements represent a
ontinuum across the actin surface and thus can be highly
odulated (9,10). A further level of complexity is imposed
y the head-to-tail overlap of adjacent TM molecules. The
nd result is a continuous, flexible coiled-coil that extends
he entire length of the thin filament, linking adjacent
unctional units and influencing cooperativity via a yet
nknown mechanism (11). In this context, the complex
ffects of the TMP1 D230N mutation are likely to reflect a
unctional disruption at multiple levels.
Although residue 230 of TM is not within the physical
ead-to-tail overlap region, it is in proximity and is likely to
e involved in important cTnT-TM interactions that are, in
art, governed by electrostatic interactions that may be
isrupted by the loss of the negatively charged aspartate
esidue. The subsequent alteration in the central relation-
hip between the Ca2 “transducer,” troponin, and the
ctinomyosin “gatekeeper,” TM, may significantly alter
he distribution of TM across the actin surface and
mpair normal cross-bridge activation, an effect that may
e transmitted across adjacent functional units linked by
he mutant TM.
It would be interesting to determine whether the HCM-
inked D175N mutation altered the Ca2-activated physical
istribution of TM in the “opposite” direction as compared
o the DCM-causing D230N mutation. The end result
ould likely be the complex and large effects on myofila-ent activation as were measured in the current study.
ecent advances in high-resolution imaging and single
yofibril force measurements will likely inform this basic
uestion and yield important information regarding the
iophysical role of TM in human DCM.
The basic question remains as to how a single amino acid
ubstitution in a component of the thin filament can result
n such a complex cardiovascular phenotype. Although the
nswer to this seemingly eternal question remains unclear,
he striking clinical similarities between the 2 unrelated
amilies in the current study afford a rare opportunity to
egin to link genotype to phenotype in DCM. The well-
efined clinical “states” provide a framework for further
tudies. One important consideration, however, is that
entricular remodeling represents the end point of many
ifferent, often initially compensatory myocellular responses
hat are secondary to the initial mutation at the level of the
arcomere. For example, animal models of HCM-linked
arcomeric mutations have exhibited downstream effects on
a2 handling, beta-adrenergic signaling, and myocardial
nergetics (12,13). Thus, as noted by the investigators, the
triking improvement of 3 of 5 affected infants may be the
esult of a 2-hit mechanism whereby the D230N TMP1
utation confers susceptibility to myocardial injury.
Along similar lines, the downstream effects of the primary
oss of sarcomeric contractile function may lead to a new
olecular “set-point,” with a corresponding decrease in
vailable cardiac reserve, thus rendering the myocardium
articularly sensitive to stresses such as systemic illness or
he plasma volume increases that occur in pregnancy.
ggressive medical therapy may provide adequate support
o allow the return to this new equilibrium state. Finally, the
linical phenotypic changes may also reflect changes in
arcomeric protein isoforms that may attenuate the primary
ffects or alterations in mutant protein dose over time. Like
ll translational studies there are many remaining questions,
ut many of them can be addressed, and the current study
rovides a wealth of information that will have an impact on
oth clinical management of early-onset DCM and our
nderstanding of the delicate interplay between sarcomeric
tructure and ventricular function.
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